What are the principal and secondary ICD-10-CM diagnosis codes for a patient with anemia associated with primary malignancy of the prostate?

Prepare for the Clever Coding Test. Study with interactive quizzes and insightful explanations. Master the concepts and boost your confidence for the actual exam!

Multiple Choice

What are the principal and secondary ICD-10-CM diagnosis codes for a patient with anemia associated with primary malignancy of the prostate?

Explanation:
The correct choice for the principal and secondary ICD-10-CM diagnosis codes for a patient with anemia associated with primary malignancy of the prostate is C61 and D63.0. In this context, C61 refers specifically to malignant neoplasm of the prostate, which is the primary malignancy in this case. D63.0 is the code for anemia in chronic disease, which applies because the anemia is secondary to the underlying malignancy. This reflects a clear and appropriate link between the two conditions: the prostate cancer is causing the anemia, thus it is coded correctly as the secondary condition. Understanding these codes is essential in clinical practice for accurately documenting the patient's primary diagnosis and any associated conditions, which can impact treatment decisions and running appropriate insurance claims.

The correct choice for the principal and secondary ICD-10-CM diagnosis codes for a patient with anemia associated with primary malignancy of the prostate is C61 and D63.0.

In this context, C61 refers specifically to malignant neoplasm of the prostate, which is the primary malignancy in this case. D63.0 is the code for anemia in chronic disease, which applies because the anemia is secondary to the underlying malignancy. This reflects a clear and appropriate link between the two conditions: the prostate cancer is causing the anemia, thus it is coded correctly as the secondary condition.

Understanding these codes is essential in clinical practice for accurately documenting the patient's primary diagnosis and any associated conditions, which can impact treatment decisions and running appropriate insurance claims.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy